Clinical Trial Search

Primary: Percentages of Subjects With a Seroresponse to Measles, Mumps, Rubella and Varicella Following Concomitant Administration of MMRV Vaccine With MenACWY-CRM Vaccine — 98…

Primary: The Ease of IUD Insertion as Rated by the Provider Using a 100mm Visual Analog Scale (VAS). — 24; 29 mm

Primary: The Safety of EXCOR® Pediatric Was Evaluated by Summarizing the Serious Adverse Event Rate Experienced While the Subject Was Supported on the Device. — 0.068; 0.066…

Primary: Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12 — 2.826; 2.824 Score on a scale

Primary: Change in the Logarithm of the Level of Human Neutrophil Elastase (HNE) Activity Measured in Sputum — 0.03; -0.17 log10 mcg/mL — p=0.14

Primary: 7-day Point Prevalence of Abstinence — 45; 22; 50 Participants

Primary: Movement — 8; 24 Participants, number

Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens

Primary: Progression-free Survival (PFS) — 8.4; 11.1 Months

Primary: Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse — 8; 12 participants — p=0.360

Primary: Progression-free Survival in BRAF V600E Mutation-positive Participants Without a History of Brain Metastases as Assessed by the Investigator and Independent Review…

Primary: Progression-Free Survival According to the Cheson Criteria by Kaplan-Meier Analysis Following Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin…

Primary: Percentage of Patients With Serum 25 Hydroxy Vitamin D3 > 30 ng/ml — 85; 29; 0 percentage of patients

Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment — 43.32; 29.44 Percentage

Primary: Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by…